PTC Therapeutics logo
PTC Therapeutics
PTCT | NASDAQ
Chart Builder DCF Calculator
$60.97
-$2.52 (-3.97%)
At close: Nov 16, 2026, 4:00 PM ET
$59.70
-$1.27 (-2.08%)
After-hours: Nov 16, 2026, 7:31 PM ET

PTC Therapeutics Company Profile

Company profile explained

Company Profile

PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for Duchenne muscular dystrophy patients in the European Economic Area and the United States. Translarna also addresses nonsense mutation Duchenne muscular dystrophy in Brazil and Russia. The company additionally commercializes Tegsedi and Waylivra for various rare conditions throughout Latin America and the Caribbean. Furthermore, in Brazil, PTC Therapeutics distributes Evrysdi as a treatment for spinal muscular atrophy (SMA) in patients aged two months and older. Leveraging its proprietary splicing platform, the company is also actively developing PTC518, a promising therapeutic candidate aimed at treating Huntington's disease. To bolster its research and development capabilities, PTC Therapeutics has established strategic collaborations, including partnerships with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation, focusing on advancing drug discovery and development research, particularly in regenerative medicine. Additionally, it collaborates with Akcea Therapeutics, Inc. for the commercialization of Tegsedi and Waylivra in the Latin America and Caribbean region. Established in 1998, PTC Therapeutics, Inc. maintains its corporate headquarters in South Plainfield, New Jersey.

Key Executives

Name Position
Matthew Klein Chief Executive Officer & Director
Linda Montella Carter Senior Vice President & Chief Information Officer
Mark Elliott Boulding Executive Vice President & Chief Legal Officer
Pierre Gravier Chief Financial Officer
Allan Steven Jacobson Co-Founder & Independent Director
Christine Utter Senior Vice President, Chief Accounting Officer & Head of People Services
Ellen Cavaleri Head of Investor Relations
Eric Pauwels Chief Business Officer
Lee Golden Executive Vice President & Chief Medical Officer
Neil Almstead Chief Technical Operations Officer

Latest SEC Filings

Date Type Title
Oct 29, 2026 10-Q Quarterly Report
Oct 29, 2026 8-K Current Report
Oct 16, 2026 4 Filing
Oct 13, 2026 4 Filing
Oct 09, 2026 4 Filing
Oct 07, 2026 4 Filing
Oct 02, 2026 4 Filing
Sep 21, 2026 8-K Current Report
Sep 18, 2026 4 Filing
Sep 11, 2026 4 Filing
View All SEC Filings ➞
PTC Therapeutics
PTC Therapeutics logo
Country United States
IPO Date Jun 20, 2013
Industry Biotechnology
Sector Healthcare
Employees 991
CEO Matthew Klein

Contact Details

500 Warren Corporate Center Drive Warren, New Jersey 07059 United States

Stock Details

Ticker Symbol PTCT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001070081
CUSIP Number 69366J200
ISIN Number US69366J2006
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.